Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: The Cox2 inhibitors and tNSAIDs description of users (CADEUS) study

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 8, 2007, Pages 891-900

  Depont, F ^a   Fourrier, A ^a,b,c   Merliere Y ^d   Droz, C ^a,b   Amouretti, M ^b,c   Begaud B ^a,b,c   Benichou J ^a,e   Moride, Y ^e,f   Velo, G P ^g   Sturkenboom, M ^h   Blin, P ^b   Moore, Nicholas ^a,b,c  

^a INSERM U657   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Bioinformatique et Chimie Moléculaire   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF VERONA   (Italy)

^h ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

COX 2 inhibitor; Drag utilisation; Gastroprotective agent; Non steroidal anti inflammatory drugs; Pharmacoepidemiology

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; FRANCE; GASTROINTESTINAL TOXICITY; GENDER; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH DISEASE; TREATMENT DURATION; UNEMPLOYMENT;

EID: 34548287418     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1388     Document Type: Article

References (37)

1. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-421.
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528. 2 p following 1528.
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284: 1247-1255.
4. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
5. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
6. Merck & Co. Merck announces voluntary Worldwide withdrawal of VIOXX®. Available at: http://vioxx.com/rofecoxib/vioxx/consumer/ index.jsp [Accessed 4 July 2005].
7. Moride Y, Ducruet T, Boivin JF, et al. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther 2005; 7: R333-R342.
8. Inman WH, Pearce G. Prescriber profile and postmarketing surveillance. Lancet 1993; 342: 1491.
9. Depont F, Fourrier A, Merliere Y, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf. (in press).
10. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.
11. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
12. Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl 2003: 43-49.
13. Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57: 86-92.
14. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
15. Mukherjee D, Topol EJ. Cox-2: where are we in 2003? Cardiovascular risk and Cox-2 inhibitors. Arthritis Res Ther 2003; 5: 8-11.
16. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.
17. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003; 16: 49-58.
18. Moride Y, Ducruet T, Boivin JF, et al. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Can J Clin Pharmacol 2005; 12: e201-e211.
19. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115: 715-720.
20. Coudert P, Dupas J, Derancourt M, et al. La prescription des coxibs: URCAM Nord Pas-de-Calais; 2004.
21. Fourrier-Reglat A, de Bailliencourt S, Molimard M, et al. Celecoxib prescription: data from the "Securite Sociale" database of the Aquitaine Regio% South-Western, France. Therapie 2005; 60: 25-29.
22. Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55: 133-136.
23. Hasford J, Moore N, Hoye K. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. Int J Clin Pharmacol Ther 2004; 42: 415-422.
24. Moore N, van Ganse E, Le Parc J, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 89-98.
25. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625-631.
26. Sany J, Bourgeois P, Saraux A, et al. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. Ann Rheum Dis 2004; 63: 1235-1240.
27. Savolainen E, Kaipiainen-Seppanen O, Kroger L, et al. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003; 30: 2460-2468.
28. Burnakis TG. Cardiovascular events and COX-2 inhibitors. JAMA 2001; 286: 2808. author reply 2811-2812.
29. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409.
30. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25: 829-835.
31. Konstam MA, Demopoulos LA. Cardiovascular events and COX-2 inhibitors. JAMA 2001; 286: 2809. author reply 2811-2812.
32. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-2288.
33. McGeer PL, McGeer EG, Yasojima K. Cardiovascular events and COX-2 inhibitors. JAMA 2001; 286: 2810. author reply 2811-2812.
34. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoathritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 89: 204-209.
35. AFSSAPS. Les anti-ulcéreux: indications chez l'adulte. Available at: http://agmed.sante.gouv.fr/htm/5/fbp/ 5530c.htm#recommandations [Accessed 29 May 2006].
36. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-2110.
37. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271-1278.